2025 Q4 -tulosraportti
69 päivää sitten
‧25 min
1,00 NOK/osake
Irtoamispäivä 22.5.
5,43%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 710 | - | - | ||
| 228 | - | - | ||
| 9 753 | - | - | ||
| 419 | - | - | ||
| 45 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.4. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16.4. · MuokattuNice movement in this recently, without there being any more interest or writings about it. We know there will be a dividend, but is there perhaps an expectation that q1 will be good? I can't find a metformin price index that gives a good picture of what we can expect in terms of earnings margins, but perhaps the prices of metformin have also risen after the war broke out! Does anyone else know?
·21.2. · MuokattuSignificant insider purchase by CEO Magnus Tolleshaug https://newsweb.oslobors.no/message/666416 Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.·21.2.Good trade there, indicates that q1 and 2026 offer growth and good results!
·23.2.Does anyone, by the way, know if they have the possibility to expand capacity in the current factory in Kragerø, or do they then possibly have to rent or build new premises? The reason I'm asking is that the strategy is to grow beyond Metformin, which I can't interpret as anything other than another API from CF pharma. They have probably stated this directly, I would think.
·12.2.7,5 % direct yield at today's price around 20 kroner is not something many can match. In addition, Vistin has significant growth potential without the need for large new investments, and very solid equity. All arrows point upwards – this could become exciting when the larger players start to position themselves. A price increase of 50 % to kr 30,- during 2026 is not unrealistic based on today's development.
·12.2.Yes, no interest-bearing debt, the investments have been made and a market that (unfortunately) has certain volume growth in the foreseeable future. A risk when the volume expansion is fully completed, could be that management gets the urge to make unprofitable, new investments.·13.2.I strongly doubt that. Just take the CF pharma investment as an example. Bought a minority stake very cheaply to look under the hood. Disciplined and cautious. Exactly what one should be when one already has a company with a high return on invested capital.- ·12.2.Incomprehensible development. The company once again delivers a strong quarter and year. This year, EPS increases to 2.7. That gives a P/E below 10 for a company with 30% return on capital. With a required rate of return of 8% and terminal growth of 2%, that gives a fair multiple of 14-15x, which implies 30kr per share.
·12.2.Why is this stock falling on good news?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
69 päivää sitten
‧25 min
1,00 NOK/osake
Irtoamispäivä 22.5.
5,43%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16.4. · MuokattuNice movement in this recently, without there being any more interest or writings about it. We know there will be a dividend, but is there perhaps an expectation that q1 will be good? I can't find a metformin price index that gives a good picture of what we can expect in terms of earnings margins, but perhaps the prices of metformin have also risen after the war broke out! Does anyone else know?
- ·21.2. · MuokattuSignificant insider purchase by CEO Magnus Tolleshaug https://newsweb.oslobors.no/message/666416 Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.·21.2.Good trade there, indicates that q1 and 2026 offer growth and good results!·23.2.Does anyone, by the way, know if they have the possibility to expand capacity in the current factory in Kragerø, or do they then possibly have to rent or build new premises? The reason I'm asking is that the strategy is to grow beyond Metformin, which I can't interpret as anything other than another API from CF pharma. They have probably stated this directly, I would think.
- ·12.2.7,5 % direct yield at today's price around 20 kroner is not something many can match. In addition, Vistin has significant growth potential without the need for large new investments, and very solid equity. All arrows point upwards – this could become exciting when the larger players start to position themselves. A price increase of 50 % to kr 30,- during 2026 is not unrealistic based on today's development.·12.2.Yes, no interest-bearing debt, the investments have been made and a market that (unfortunately) has certain volume growth in the foreseeable future. A risk when the volume expansion is fully completed, could be that management gets the urge to make unprofitable, new investments.·13.2.I strongly doubt that. Just take the CF pharma investment as an example. Bought a minority stake very cheaply to look under the hood. Disciplined and cautious. Exactly what one should be when one already has a company with a high return on invested capital.
- ·12.2.Incomprehensible development. The company once again delivers a strong quarter and year. This year, EPS increases to 2.7. That gives a P/E below 10 for a company with 30% return on capital. With a required rate of return of 8% and terminal growth of 2%, that gives a fair multiple of 14-15x, which implies 30kr per share.
- ·12.2.Why is this stock falling on good news?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 710 | - | - | ||
| 228 | - | - | ||
| 9 753 | - | - | ||
| 419 | - | - | ||
| 45 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.4. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
69 päivää sitten
‧25 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.4. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
1,00 NOK/osake
Irtoamispäivä 22.5.
5,43%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16.4. · MuokattuNice movement in this recently, without there being any more interest or writings about it. We know there will be a dividend, but is there perhaps an expectation that q1 will be good? I can't find a metformin price index that gives a good picture of what we can expect in terms of earnings margins, but perhaps the prices of metformin have also risen after the war broke out! Does anyone else know?
- ·21.2. · MuokattuSignificant insider purchase by CEO Magnus Tolleshaug https://newsweb.oslobors.no/message/666416 Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.·21.2.Good trade there, indicates that q1 and 2026 offer growth and good results!·23.2.Does anyone, by the way, know if they have the possibility to expand capacity in the current factory in Kragerø, or do they then possibly have to rent or build new premises? The reason I'm asking is that the strategy is to grow beyond Metformin, which I can't interpret as anything other than another API from CF pharma. They have probably stated this directly, I would think.
- ·12.2.7,5 % direct yield at today's price around 20 kroner is not something many can match. In addition, Vistin has significant growth potential without the need for large new investments, and very solid equity. All arrows point upwards – this could become exciting when the larger players start to position themselves. A price increase of 50 % to kr 30,- during 2026 is not unrealistic based on today's development.·12.2.Yes, no interest-bearing debt, the investments have been made and a market that (unfortunately) has certain volume growth in the foreseeable future. A risk when the volume expansion is fully completed, could be that management gets the urge to make unprofitable, new investments.·13.2.I strongly doubt that. Just take the CF pharma investment as an example. Bought a minority stake very cheaply to look under the hood. Disciplined and cautious. Exactly what one should be when one already has a company with a high return on invested capital.
- ·12.2.Incomprehensible development. The company once again delivers a strong quarter and year. This year, EPS increases to 2.7. That gives a P/E below 10 for a company with 30% return on capital. With a required rate of return of 8% and terminal growth of 2%, that gives a fair multiple of 14-15x, which implies 30kr per share.
- ·12.2.Why is this stock falling on good news?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 710 | - | - | ||
| 228 | - | - | ||
| 9 753 | - | - | ||
| 419 | - | - | ||
| 45 | - | - |
Välittäjätilasto
Dataa ei löytynyt